Mp29-13 real-world study on darolutamide, enzalutamide, and apalutamide for nonmetastatic castration-resistant prostate cancer patients using a urology network in the united states (dear study)

You have accessJournal of UrologyCME1 Apr 2023MP29-13 REAL-WORLD STUDY ON DAROLUTAMIDE, ENZALUTAMIDE, AND APALUTAMIDE FOR NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS USING A UROLOGY NETWORK IN THE UNITED STATES (DEAR STUDY) Neal D. Shore, Nasreen Khan, Niculae Constantinovici, Javeed Khan, Guifang Chen, Julie Xu, Jorge Ortiz, Alicia K. Morgans, and Daniel J. George Neal D. ShoreNeal D. Shore More articles by this author , Nasreen KhanNasreen Khan More articles by this author , Niculae ConstantinoviciNiculae Constantinovici More articles by this author , Javeed KhanJaveed Khan More articles by this author , Guifang ChenGuifang Chen More articles by this author , Julie XuJulie Xu More articles by this author , Jorge OrtizJorge Ortiz More articles by this author , Alicia K. MorgansAlicia K. Morgans More articles by this author , and Daniel J. GeorgeDaniel J. George More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003257.13AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Second-generation androgen receptor inhibitors (ARIs) are recommended for patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) due to their ability to prolong overall survival and metastasis-free survival. Besides efficacy, drug tolerance is also important for these patients as they are often asymptomatic from their disease. However, there is limited information on real-world (RW) outcomes from the use of different ARIs. DEAR is the first study using a single data source to assess RW utilization and outcomes of darolutamide (daro), enzalutamide (enza), and apalutamide (apa) in patients with nmCRPC. METHODS: This is a retrospective chart review study using electronic medical records from the Precision Point Specialty network of US urology practices. Eligible patients had nmCRPC, no prior novel hormonal therapy, and initiated first ARI treatment from August 2019 to March 2022. Patients were stratified into 3 cohorts based on the first prescribed ARI in the nmCRPC stage. This interim report describes the proportions of patients who discontinued initial ARI treatment, patients who progressed to metastatic CRPC (mCRPC), and the estimated probability of discontinuation/progression at 6, 12, 18, and 24 months using Kaplan-Meier estimates. RESULTS: In total, 666 patients were included (daro/enza/apa, n=276/280/110). Median age (80/79/80 years), White race (68%/69%/74%), and median prostate-specific antigen doubling time (6.7/6.0/7.8 months) were similar in the daro/enza/apa cohorts at baseline. Median length of follow-up was similar (Table). Overall, fewer patients discontinued treatment in the daro cohort (27.9%) vs 37.9%/45.5% for enza/apa, and fewer patients progressed to mCRPC in the daro cohort (18.1%) compared with enza or apa (28.9%/25.5%). Generally, the estimated probability of discontinuation/progression was numerically lower for daro compared with enza or apa. CONCLUSIONS: In this interim analysis, despite similar baseline characteristics, fewer daro patients discontinued treatment or progressed to mCRPC compared with enza or apa. Source of Funding: Bayer HealthCare © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e386 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Neal D. Shore More articles by this author Nasreen Khan More articles by this author Niculae Constantinovici More articles by this author Javeed Khan More articles by this author Guifang Chen More articles by this author Julie Xu More articles by this author Jorge Ortiz More articles by this author Alicia K. Morgans More articles by this author Daniel J. George More articles by this author Expand All Advertisement PDF downloadLoading ...